Back to discover

Protein / target

Interleukin-7

Encoded byIL7P13232Homo sapiensSwiss-Prot
Antibody-tractable
Druggability
UniProt loc high conf
3
Research papers

Protein at a glance

Biological role

Interleukin-7 receptor binding

Strongest disease association

Severe Combined Immunodeficiency

Via encoding gene IL7 · Genetic literature evidence · score 0.61

Research activity

Emerging research

3 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Hematopoietic cytokine that plays an essential role in the development, expansion, and survival of naive and memory T-cells and B-cells thereby regulating the number of mature lymphocytes and maintaining lymphoid homeostasis.

View complete UniProt function annotation

Hematopoietic cytokine that plays an essential role in the development, expansion, and survival of naive and memory T-cells and B-cells thereby regulating the number of mature lymphocytes and maintaining lymphoid homeostasis (PubMed:25870237, PubMed:7527823). Mechanistically, exerts its biological effects through a receptor composed of IL7RA subunit and the cytokine receptor common subunit gamma/CSF2RG (PubMed:8128231). Binding to the receptor leads to activation of various kinases including JAK1 or JAK3 depending on the cell type and subsequently propagation of signals through activation of several downstream signaling pathways including the PI3K/Akt/mTOR or the JAK-STAT5 (PubMed:18523275, PubMed:20974963)

Subcellular location

Secreted
Domains and Gene Ontology detail (18)

Gene Ontology

  • Cextracellular matrix
  • Cextracellular region
  • Cextracellular space
  • Fcytokine activity
  • Fgrowth factor activity
  • Finterleukin-7 receptor binding
  • Panimal organ morphogenesis
  • Pbone resorption
  • Pcell-cell signaling
  • Pcytokine-mediated signaling pathway
  • Phumoral immune response
  • Pinterleukin-7-mediated signaling pathway

177 aa · 20 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOImmune signallingUniProt · GO
View supporting evidence

Cell proliferation & survival

  • ·positive regulation of cell population proliferation

Immune signalling

  • ·Hematopoietic cytokine that plays an essential role in the development, expansion, and s…
  • ·cytokine activity
  • ·interleukin-7 receptor binding
  • ·cytokine-mediated signaling pathway

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene IL7

Gene-level evidence surfaced through the gene IL7that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Severe Combined Immunodeficiency
0.50Limited support

Genetic literature evidence dominant · Open Targets 0.37

Neoplasms
0.45Limited support

Genetic evidence dominant · Open Targets 0.25

Basal cell carcinoma
0.43Limited support

Genetic evidence dominant · Open Targets 0.26

Lupus Erythematosus, Systemic
0.42Limited support

Genetic evidence dominant · Open Targets 0.25

Cardiomyopathies
0.41Limited support

Genetic evidence dominant · Open Targets 0.24

View evidence synthesis (5)
Severe Combined ImmunodeficiencyLimited support
0.50
agreement 0.350.65
Genetic literature95%Literature5%

Open Targets aggregate 0.37 · 2 independent evidence families

NeoplasmsLimited support
0.45
agreement 0.310.58
Genetic74%Literature26%

Open Targets aggregate 0.25 · 2 independent evidence families

Basal cell carcinomaLimited support
0.43
agreement 0.290.57
Genetic100%Literature0%

Open Targets aggregate 0.26 · 2 independent evidence families

Lupus Erythematosus, SystemicLimited support
0.42
agreement 0.280.56
Genetic93%Literature7%

Open Targets aggregate 0.25 · 2 independent evidence families

CardiomyopathiesLimited support
0.41
agreement 0.270.55
Genetic95%Literature5%

Open Targets aggregate 0.24 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Severe Combined Immunodeficiency0.37
Basal cell carcinoma0.26
Lupus Erythematosus, Systemic0.25
Neoplasms0.25
Cardiomyopathies0.24

Tractability

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (3)
AB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMM

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

adverse eventsClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Research activity

3 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.